DIABETES MELLITUS, CHRONIC COMPLICATION IN PATIENTS WITH ACROMEGALY: CASE REPORT AND REVIEW OF THE LITERATURE

Authors

  • Corina GALESANU University of Medicine and Pharmacy”Grigore T. Popa”- Iasi
  • C. BUZDUGA University of Medicine and Pharmacy”Grigore T. Popa”- Iasi
  • A. FLORESCU University of Medicine and Pharmacy”Grigore T. Popa”- Iasi
  • Liliana MOISII University of Medicine and Pharmacy”Grigore T. Popa”- Iasi
  • V. CIUBOTARU Neurosurgery Hospital “Bagdasar-Arseni” Bucuresti-Romania

Abstract

Disturbances of glucose metabolism are frequently observed in patients with acromegaly.  Excess amounts of GH and IGF1 interacts with metabolic regulation, and indeed, GH hypersecretion is associated with hepatic and peripheral insulin resistance; this and also other mechanisms are involved in the development of diabetes mellitus. It can quickly improve if the levels of GH decline after the therapy. Case report: We present a patient of 54 years old, admitted in the clinic in 2009, with diagnosis of acromegaly. MRI scan reveals an expansive pituitary tumor 15/16/17 mm. Values of GH, IGF1 and blood glucose were much above normal. Body mass index 27, 5 kg/m2. After 12 months of a medical treatment with somatostatin analogues, the evolution of blood parameters was favorable, but the patient has discontinued his treatment. At the hospitalization in 2012 there is a precarious control of the diabetes under oral antidiabetic agents. A new treatment has been applied: it was practiced surgical transsphenoidal ablation. At last admit, May 2014, the value IGF1 has been normal, GH has been below 1 ng/mL, and HbA1c was 5.27%. Dyslipidemic syndrome has been constantly present; the values of triglycerides and cholesterol should be a little more upper limit. Conclusions: Following successful treatment of acromegaly with surgery, glucose tolerance improves. Balancing type 2 diabetes, with return to normal HbA1c and the decrease in cholesterol and triglycerides values, represents the result of favorable normalization GH in our patients with acromegaly.

Author Biographies

  • Corina GALESANU, University of Medicine and Pharmacy”Grigore T. Popa”- Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)

  • C. BUZDUGA, University of Medicine and Pharmacy”Grigore T. Popa”- Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)

  • A. FLORESCU, University of Medicine and Pharmacy”Grigore T. Popa”- Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)

  • Liliana MOISII, University of Medicine and Pharmacy”Grigore T. Popa”- Iasi

    Faculty of Medicine
    Department of Surgery

References

1. Melmed S. Acromegaly. NEJM 1990; 322: 966-977.
2. Pannett A A J, Thakker R V. Multiple endocrine neoplasia type 1. Endocr Relat Cancer 1999; 6: 449-473.
3. Loeb M. Ein Erklärungsversuch der verschiedenartigen Temperaturverhaltnisse bei der tuberku-losen Basilarmeningitis. Deutsches Arch f. klin Med. 1884; 34: 443-447.
4. Darragh JH, Shaw WM. Acromegaly and Diabetes. Canad MAJ 1954; 64: 146-150.
5. Găleşanu C, Munteanu I, Radeanu C, Zbranca E. Diabetul zaharat in acromegalie. Clinica Iasi, 2000; I(1): 19-21.
6. Mukherjee, J J, Majumdar, Sujoy. Acromegaly [internet]. 2014 Aug 13; Diapedia 4104085191 rev. no. 29. Available from: http://dx.doi.org/10.14496/dia.4104085191.29
7. Clemmons DR, VanWyk JJ, Ridgway EC, Kliman B, Kjellberg RN ,Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. New Engl J Med 1979; 301: 1138–1142.
8. Colao A, Ferone D, Marzullo P , Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102–152.
9. Fieffe S, Morange I, Petrossians P et al. Diabetes in Acromegaly: prevalence, risk factors and evolution: data from French Acromegaly Registry. Eur J Endocrinol 2011; 164: 877-884.
10. Kreze A, Kreze-Spirova E & Mikulecky M. Risk factors for glucose intolerance in active acromeg-aly. Brazil J Med Biol Res 2001; 34: 1429–1433.
11. Nabarro JD .Acromegaly. Clin Endocrinol 1987, 26 , 481–512.
12. Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P , Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2013; 17: 81–89.
13. Verschoor L, Lamberts SW, Uitterlinden P , Del PE. Glucose tolerance during long term treatment with a somatostatin analogue. BMJ 1986; 293: 1327–1328.
14. Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, Pivonello R. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 2009; 94: 2907–2914.
15. Møller N & Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30: 152–177.
16. Biering H, Knappe G, Gerl H, Lochs H. Prevalence of Diabetes in Acromegaly and Cushing Syn-drome. Acta Med Austriaca 2000; 27: 27–31.
17. Møller N, Schmitz O, Jøorgensen JO et al. Basal- and insulinstimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992; 74: 1012–1019.
18. Puder JJ, Nilavar S, Post KD , Freda PU. Relationship between disease-related morbidity and bio-chemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 2005; 90: 1972–1978.
19. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA ,Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008; 93: 61–67.
20. Jaffrain-Rea ML, Moroni C, Baldelli R et al. Relationship between blood pressure and glucose tolerance in acromegaly .Clin Endocrinol 2001; 54: 189–195.
21. Jaffrain-Rea M, Minniti G, Moroni C et al. Impact of successful transsphenoidal surgery on cardio-vascular risk factors in acromegaly. Eur J Endocrinol 2003; 148: 193–201.
22. Mestron A, Webb SM, Astorga R et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espanol De Acromegalia, Rea). Eur J Endocrinol 2004; 151: 439–446.
23. Bex M, Abs R, T’Sjoen G,et al. Acrobel-the belgian registry on acromegaly: a survey ofthe ‘real-life’ outcome in 418 acromegalic subjects. EurJ Endocrinol 2007; 157: 399–409.
24. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P , Arosio M. Effects of two different somato-statin analogs on glucose tolerance in acromegaly. J Endocrinol Investig 2002; 25: 502–507.
25. Colao A, Auriemma RS, Galdiero M, Lombardi G , Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clini Endocrinol Metab 2009; 94: 3746–3756.
26. Kinoshita Y, Fujii H, Takeshita A, & all. Impaired glucose metabolismin Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur J Endocrinol 2011; 164: 467–473.

Additional Files

Published

2015-03-31

Issue

Section

INTERNAL MEDICINE - PEDIATRICS